2019 Interviews
Rethinking Gene Expression Using the Synthetic C3P3 Transcription System
Philippe H. Jais, MD, PhD, President and CSO, Eukarÿs SAS
View the interview
A Multi-Purpose Protein Expression Platform
Jose M. Martinez-Costas, PhD, Profezsor Titular, Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS); Departamento de Bioquímica e Bioloxía Molecular, Universidade de Santiago de Compostela
View the interview
2018
Podcasts
Transient Protein Gene Expression and Biotherapeutics: Advances, Challenges, Solutions and Clinical Use
Florian M. Wurm, Dr. rer. nat., Professor Emeritus, Swiss Federal Institute of Technology Lausanne (EPFL); Founder, Chairman, ExcellGene SA
Dr. Florian M. Wurm, Swiss Federal Institute of Technology Lausanne (EPFL) and ExcellGene SA speaks to Cambridge Healthtech Institute on 9 July 2018. He will be the keynote presenter during the Optimising Expression Platforms conference at
PEGS Europe, 12-16 November 2018 in Lisbon, Portugal.
Topics Questions Include:
1. Let's talk about transient protein expression. What advances do you foresee in this approach for enabling efficient engineering and expression of therapeutic proteins in the next decade?
2. What potential solutions seem promising for some challenges?
3. Are there promising glimpses into using transient protein gene expression for clinical use today?
4. You'll be discussing “Transient Protein (Gene) Expression:
From R&D towards Pharmaceutical Manufacturing” during your keynote presentation on 14 November. What's the main theme you'd like to convey to your audience of protein engineers and researchers?
For more information, please visit PEGSummitEurope.com/Optimising-Protein-Expression
Interviews
Structural Biology of Membrane Proteins: Expression Tricks, and to Solubilize or Not to Solubilize
Dirk Linke, PhD, Professor, Genetics and Evolutionary Biology, Biosciences, University of Oslo
View the Interview
Taming Random Conjugation: A General Approach for Equimolar Linking of Proteins and Payloads
Sergii Kolodych, PhD, CSO, Syndivia SAS
View the Interview
2017
Podcasts
Widening the Therapeutic Index: The Next Generation of Antibody-Drug Conjugates (ADCs)
John M. Lambert, Ph.D., Executive Vice President Emeritus and Distinguished Research Fellow, ImmunoGen, Inc.
This podcast highlights the Plenary Keynote presentation that John Lambert will be giving at PEGS Europe, 13 November 2018 in Lisbon, Portugal. Dr. Lambert discusses the difficulties of bringing novel constructs to market; advice for people
introducing new ADC products in the clinical setting; and some of the most exciting new developments and emerging applications for ADCs. He shares his thoughts on ADCs that target both cancer initiating cells and differentiated cancer
cells and clinical results; escape mechanisms tumor cells use to avoid destruction by ADCs; how perception shifted over the last three –four years on ADCs; and how can ADCs be combined with immuno-oncology approaches.
For more information, please visit www.PEGSummitEurope.com/Keynote
Interviews
A New Strategy To Assess Ligand Or Solution-Based Stability Of Aggregation-Prone Proteins Using An Automated Chaperonin Biolayer Interferometry Platform
Mark T. Fisher, Ph.D., Professor, University of Kansas Medical Center
View the Interview
Characterization And Control Of Particulates, From Aggregates To Visible Particles
Patricia Winter Cash, Ph.D., Independent Consultant
View the Interview
Production of Human Aldehyde Oxidase (AO) in Baculovirus-Infected Insect Cells (BEVS)
Ciarán N. Cronin, Ph.D., Associate Research Fellow, Head, Parallel Protein Production Group, and Group Leader, Gene-to-Structure, Pfizer Global R&D
View the Interview
Improving Protein Expression Yields with Adaptive Evolutionary Engineering and Protein Production Technologies
Antonio Roldao, Ph.D., Senior Scientist, Animal Cell Technology Unit, Instituto de Biologia Experimental e Tecnológica (iBET)
View the Interview
Using 'Big Data' and Synthetic Biology for Gene Expression Modeling, Engineering, and Understanding
Tamir Tuller, Ph.D., Ph.D., Associate Professor and Head, Laboratory of Computational Systems and Synthetic Biology, Tel Aviv University
View the Interview
2016
Podcasts
Evolution of Recombinant Protein Expression and Improvements in Engineering CHO Cell Lines
Bjørn Voldborg, MSc, Director, CHO Cell Line Development, Novo Nordisk Foundation Center for Biosustainability (CFB), DTU Biosustain, Technical University of Denmark
Bjørn Voldborg of Technical University of Denmark speaks to Cambridge Healthtech Institute on August 16, 2016. He will be a featured presenter at the Optimising Expression Platforms conference during PEGS Europe, 31 October - 4 November
in Lisbon, Portugal.
Topics Include: technological advancements in engineering CHO cell lines for increasing product yield and quality, challenges in recombinant protein expression over the last 20 years, and production of recombinant proteins
as a science, not a service function.
Immune Checkpoint in Melanoma
Paolo Ascierto, M.D., Director, Melanoma, Cancer Immunotherapy & Innovative Therapies, Istituto Nazionale Tumori Napoli
Dr. Ascierto will be discussing a historical perspective in treating melanoma and outline current clinical trials and real-world experience in immune checkpoint in melanoma, and detail what he considers some of the most exciting discoveries
in the field.
Topics Include: MOC, PGE, IMX, IMT, CAR, Checkpoint inhibition, Immunotherapy, CAR Therapy, Therapeutic Antibodies
How Display and Signaling of CAR Molecules Can Be Used to Redirect the Specificity of Human T Cells
Hinrich Abken, Ph.D., Professor, Genetics & Immunology, Center for Molecular Medicine Cologne, University of Cologne
Dr. Abken will be discussing next generation CARs, comparison to other approaches, current efforts to improve on CAR molecules and advice for people in the field.
Topics Include: PGD, PGE, IMX, IMT, CAR, Phage display, immunotherapy, CAR therapy, display of antibodies
Interviews
Challenges & Lessons Learned in ADC CMC Development & Outsourcing
Jens Lohrmann, Ph.D., Senior Global Program Manager, Translational Clinical Oncology, Novartis Institutes for BioMedical Research
View the Interview | Download PDF
Continuous Aqueous Two-Phase Extraction of Proteins – Novel Process Windows by Increasing Protein Solubility
Christoph Brandenbusch, Ph.D., Group Leader, Department of Biochemical and Chemical Engineering, Laboratory of Thermodynamics, TU Dortmund University
View the Interview | Download PDF
Chemical Pharmacology of Protein Conjugates
Gonçalo J.L. Bernardes, Ph.D., Principal Investigator, Chemistry, University of Cambridge
View the Interview | Download PDF
Case Study: Human Kinase Crystallization, Phosphatase Co-Expression
Mario Lebendiker, Ph.D., Head, Protein Purification Facilities, Wolfson Centre for Applied Structural Biology, The Hebrew University of Jerusalem
View the Interview | Download PDF
Advancement in Antibody Drug Conjugates: A Step Closer to Creating Magic Bullets against Deadly Cancers
Rakesh Dixit, Ph.D., DABT, Vice President, Research & Development, and Global Head, Biologics Safety Assessment, MedImmune (A member of AstraZeneca Group)
View the Interview | Download PDF
2015
Video
Interview with Gregory Weiss
Podcast
CHO Cells and Recombinant Protein Production across Expression Platforms
Niall Barron, Ph.D., Program Leader, Mammalian Cell Engineering, National Institute for Cellular Biotechnology, Dublin City University
Dr. Niall Barron of Dublin City University speaks to CHI on August 28, 2015. Dr. Barron will be presenting during the Engineering Expression Systems conference at the 2015 PEGS Europe Summit, 2-6 November in Lisbon, Portugal.
Topics include: CHO cell line engineering, accelerating recombinant protein production with existing and novel expression platforms, challenges, microRNA manipulation to boost recombinant protein productivity and manufacturing
of biopharmaceuticals in Ireland.
Interviews
Microbial Expression Systems, Scale-Up and Future Considerations
Georg Klima, Executive Director, Process Science Austria, Biopharmaceuticals Division, Boehringer Ingelheim
Cell Line Platforms and Expression of Novel Bispecific Antibodies
Pierre Moretti, Ph.D., Head, Cell Line Development, Glenmark Pharmaceuticals
Interview with Oliver Spadiut
Oliver Spadiut, Ph.D., Group Leader, Integrated Bioprocess Development, Biochemical Engineering, Vienna University of Technology
Interview with Eric Lacoste
Eric Lacoste, Ph.D., ADC Team Leader, Chemistry & Biotechnology Development, Sanofi-Aventis Research & Development
Protein Function and High-Throughput Expression of Recombinant Proteins
Ray Owens, Ph.D., Head, Oxford Protein Production Facility-UK, Research Complex at Harwell and Professor, Molecular Biology, University of Oxford